Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $8.39, but opened at $8.19. Vir Biotechnology shares last traded at $8.17, with a volume of 95,307 shares.
Wall Street Analysts Forecast Growth
A number of brokerages recently commented on VIR. Leerink Partners raised their price objective on shares of Vir Biotechnology from $18.00 to $20.00 and gave the company an "outperform" rating in a research report on Monday, January 13th. JPMorgan Chase & Co. lifted their price target on Vir Biotechnology from $10.00 to $14.00 and gave the company a "neutral" rating in a research note on Thursday, January 9th. Morgan Stanley upgraded Vir Biotechnology from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $10.00 to $20.00 in a research report on Thursday, January 9th. Needham & Company LLC reissued a "buy" rating and issued a $19.00 target price on shares of Vir Biotechnology in a report on Thursday, February 27th. Finally, Barclays increased their price target on shares of Vir Biotechnology from $26.00 to $31.00 and gave the company an "overweight" rating in a report on Friday, February 28th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $35.67.
Read Our Latest Report on VIR
Vir Biotechnology Stock Down 1.8 %
The firm's fifty day simple moving average is $9.51 and its 200-day simple moving average is $8.48. The company has a market cap of $1.11 billion, a PE ratio of -2.06 and a beta of 1.17.
Vir Biotechnology (NASDAQ:VIR - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.85) by $0.09. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The firm had revenue of $12.37 million for the quarter, compared to analyst estimates of $8.14 million. On average, analysts predict that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.
Insider Activity at Vir Biotechnology
In related news, Director George A. Scangos sold 10,964 shares of Vir Biotechnology stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total value of $107,556.84. Following the completion of the transaction, the director now directly owns 708,295 shares in the company, valued at approximately $6,948,373.95. This trade represents a 1.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Verneuil Vanina De sold 7,373 shares of the stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total value of $67,389.22. Following the transaction, the executive vice president now directly owns 79,460 shares in the company, valued at approximately $726,264.40. This represents a 8.49 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 30,859 shares of company stock valued at $326,458. 15.60% of the stock is owned by insiders.
Institutional Investors Weigh In On Vir Biotechnology
Several institutional investors and hedge funds have recently made changes to their positions in VIR. Point72 Asia Singapore Pte. Ltd. bought a new stake in Vir Biotechnology during the fourth quarter valued at $42,000. SBI Securities Co. Ltd. acquired a new position in shares of Vir Biotechnology in the 4th quarter valued at about $60,000. PNC Financial Services Group Inc. grew its position in shares of Vir Biotechnology by 31.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company's stock valued at $61,000 after buying an additional 1,999 shares during the last quarter. KBC Group NV raised its stake in Vir Biotechnology by 136.5% during the fourth quarter. KBC Group NV now owns 8,970 shares of the company's stock worth $66,000 after acquiring an additional 5,177 shares during the period. Finally, CIBC Asset Management Inc bought a new position in Vir Biotechnology in the fourth quarter worth about $74,000. 65.32% of the stock is owned by institutional investors and hedge funds.
Vir Biotechnology Company Profile
(
Get Free Report)
Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
Recommended Stories
Before you consider Vir Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vir Biotechnology wasn't on the list.
While Vir Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
